{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:51:22Z","timestamp":1792662682386,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019298","name":"Greenwich Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.yebeh.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T23:03:36Z","timestamp":1531263816000},"page":"131-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"special_numbering":"C","title":["Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes"],"prefix":"10.1016","volume":"86","author":[{"given":"Orrin","family":"Devinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Verducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Laux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Filloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy P.","family":"Szaflarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Wilfong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong D.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E.","family":"Seltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Martina","family":"Bebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-1797","authenticated-orcid":false,"given":"Daniel","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.05.013_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmg.2011.12.010","article-title":"Clinical review of genetic epileptic encephalopathies","volume":"55","author":"Noh","year":"2012","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"4","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebcr.2015.10.001","article-title":"Epilepsy with myoclonic-atonic seizures (Doose syndrome): When video-EEG polygraphy holds the key to syndrome diagnosis","volume":"5","author":"Dragoumi","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0020","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13813","article-title":"Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients","volume":"8","author":"Lim","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","article-title":"Cannabinoids in treatment-resistant epilepsy: A review","volume":"70","author":"O\u2019Connell","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"10125","key":"10.1016\/j.yebeh.2018.05.013_bb0030","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCASE4): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0040","first-page":"103","article-title":"Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature","volume":"4","author":"Mortati","year":"2007","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)30824-4","article-title":"Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0060","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases","volume":"32","author":"Gofshteyn","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0070","author":"Zynerba Pharmaceuticals"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpn.2013.07.005","article-title":"Epilepsy in Aicardi-Gouti\u00e8res syndrome","volume":"18","author":"Ramantani","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/epi.12530","article-title":"A survey of seizures and current treatments in 15q duplication syndrome","volume":"55","author":"Conant","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0090","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1469-8749.2010.03744.x","article-title":"Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress","volume":"52","author":"Kelley","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0095","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1212\/WNL.0000000000003352","article-title":"Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder","volume":"87","author":"Fehr","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0100","first-page":"437S","article-title":"The Cannabinoids as Potential Antiepileptics","volume":"21","author":"Karler","year":"1961","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0105","first-page":"312","article-title":"Changes in CNS Sensitivity to Cannabinoids with Repeated Treatment: Tolerance and Auxoesthesia","volume":"54","author":"Karler","year":"1984","journal-title":"Natl Inst Drug Abuse Mech Tolerance Depend"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0115","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs. UAB CBD Program","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0120","article-title":"The effect of Epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs children and young adults with treatment-resistant epilepsy in an expanded access program","author":"Friedman","year":"2014","journal-title":"American Epilepsy Society"},{"issue":"14","key":"10.1016\/j.yebeh.2018.05.013_bb0125","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"A randomized, dose-ranging safety trial of cannabidiol in Dravet Syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome [Abstract]","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2018.05.013_bb0135","first-page":"98-014","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3)","volume":"89","author":"Patel","year":"2017","journal-title":"Neurology"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018301914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018301914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:27Z","timestamp":1761503067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018301914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":27,"alternative-id":["S1525505018301914"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.013","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}